Your shopping cart is currently empty

Nicotinamide riboside malate is a compound formed by the salt of nicotinamide riboside and malic acid. Nicotinamide riboside malate acts as a precursor to NAD⁺ and promotes the elevation of NAD⁺ levels within cells by supplementing the NR pathway, thereby participating in energy metabolism and the regulation of mitochondrial function.

| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 50 mg | $31 | - | In Stock | |
| 100 mg | $44 | - | In Stock | |
| 500 mg | $71 | - | In Stock | |
| 1 g | $93 | - | In Stock | |
| 5 g | $228 | - | In Stock | |
| 10 g | $338 | - | In Stock |
| Description | Nicotinamide riboside malate is a compound formed by the salt of nicotinamide riboside and malic acid. Nicotinamide riboside malate acts as a precursor to NAD⁺ and promotes the elevation of NAD⁺ levels within cells by supplementing the NR pathway, thereby participating in energy metabolism and the regulation of mitochondrial function. |
| In vitro | Nicotinamide riboside malate (0.5 nM; 24 hours) reduces the acetylation status of Ndufa9 and SOD2[1]. Nicotinamide riboside malate increases intracellular and mitochondrial NAD + content in C2C12, Hepa1.6, and HEK293 cells in a concentration-dependent manner at concentrations ranging from 1-1000 μM[1]. Nicotinamide riboside malate boosts NAD to restore antiviral poly(ADP-ribose) polymerase (PARP) functions to support innate immunity for coronavirus (CoVs), a cause of COVID-19[3]. Western Blot Analysis, Cell Line: HEK293T cells Concentration: 0.5 nM Incubation Time: 24 hours Result: Reduced the acetylation status of Ndufa9 and SOD2 [1]. |
| In vivo | Chronic supplementation with Nicotinamide riboside malate (p.o.; 400 mg/kg/day; for 16 weeks) elevates plasma and intracellular NAD+ levels in a tissue-specific manner[1]. This effect was observed in a study conducted on 10-week-old C57Bl/6J mice administered orally with a daily dosage of 400 mg/kg for a period of 16 weeks, leading to an increase in both plasma and intracellular NAD+ content, highlighting the compound's potential for targeted therapeutic applications. Chronic Nicotinamide riboside malate (p.o.; 400 mg/kg/day; for 16 weeks) supplementation increases plasma and intracellular NAD + content in a tissue-specific manner[1]. |
| Molecular Weight | 388.33 |
| Formula | C15H20N2O10 |
| Cas No. | 2415659-01-5 |
| Smiles | O[C@H]1[C@@H](O[C@H](CO)[C@H]1O)[N+]=2C=C(C(N)=O)C=CC2.[C@H](CC([O-])=O)(C(O)=O)O |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | |||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: 116.67 mg/mL (300.44 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
H2O
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.